X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Under the terms of the agreement, AstraZeneca will have exclusive rights to Omniose’s proprietary bioconjugation platform for up to three years, which allows for the development of high-quality vaccines against a range of bacterial pathogens.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: AstraZeneca
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration January 05, 2024
Details:
The funding will be used for the development of a Group B Streptococcus vaccine using Omniose bioconjugate vaccine platform which enables the precise enzymatic attachment of virtually any bacterial polysaccharide antigen to engineered carrier proteins within E. coli cell.
Lead Product(s): GBS Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: DiscoveryProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $3.0 million Upfront Cash: Undisclosed
Deal Type: Funding September 27, 2023
Details:
Funds from this award as well as other NIH grants awarded to Omniose will support the development and IND-enabling studies of bioconjugate vaccines that target the most clinically relevant capsular polysaccharides and O-antigen polysaccharides of K. pneumoniae.
Lead Product(s): Bioconjugate Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: National Institute of Allergy and Infectious Diseases
Deal Size: $3.6 million Upfront Cash: Undisclosed
Deal Type: Funding October 11, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
